表紙
市場調査レポート

全身性エリテマトーデスの治療薬:世界市場

Drugs for Treating Systemic Lupus Erythematosus: Global Markets

発行 BCC Research 商品コード 298486
出版日 ページ情報 英文 129 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.50円で換算しております。
Back to Top
全身性エリテマトーデスの治療薬:世界市場 Drugs for Treating Systemic Lupus Erythematosus: Global Markets
出版日: 2014年03月28日 ページ情報: 英文 129 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

全身性エリテマトーデス(SLE)は、症状の重い慢性自己免疫疾患です。これまでに承認を受けた市販の治療薬は少なく、未対応の医療ニーズが存在する重要な領域といえますが、現在多くの企業が新たな治療薬の開発に取り組んでいます。このため、世界市場における治療薬の売上高は、2013年の9億5,020万ドルから2018年には26億ドルに伸びる見通しであり、この間の年平均成長率は22.4%になると予想されています。

当レポートは、SLEの治療に用いられる医薬品や治療法の世界市場を概観し、市場のトレンドを分析するとともに、2018年までの見通しを示したもので、業界の構造や各国政府の規制、現在開発が進められている技術など今後の需要に影響すると見られる要因や各社が開発を進めている製品のパイプラインに関する分析のほか、主要メーカーのプロファイルも盛り込み、概略以下の構成でお届けします。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 概要

  • 兆候と症状
  • 紅斑性狼瘡のタイプ
    • 全身性エリテマトーデス(SLE)
    • 皮膚エリテマトーデス(CLE)
    • 薬剤誘発性ループス
    • 新生児エリテマトーデス
  • 病態生理学
    • 疾病の定義
    • 臨床症状
  • 進行と重症度
  • 病因
    • 遺伝学的要因
    • 環境的要因
    • ホルモンの要因
  • 疫学と患者数
    • 米国
    • フランス
    • ドイツ
    • 英国
    • スペイン
    • イタリア
    • 日本
  • 全身性エリテマトーデスと診断され薬物治療を受けている人の数

第4章 現在の医療と市場の概況

  • 診断検査と一般の認知度
    • 主な診断検査
  • 臨床勧告と診断アルゴリズム
  • 鑑別診断
  • 紹介パターン
    • 米国
    • フランス
    • ドイツ
    • 英国
    • スペイン
    • イタリア
    • 日本

第5章 現在の治療法

  • 抗マラリア薬
  • 非ステロイド系抗炎症薬(NSAIDS)
  • 副腎皮質ステロイド
  • 細胞毒性薬および免疫抑制薬
    • シクロホスファミド
    • ミコフェノール酸モフェチル
    • メトトレキサート
    • シクロスポリン
    • タクロリムス
  • 生物製剤
    • B細胞標的治療
    • BLyS阻害剤(ベリムマブ)
  • SLEに対する治療薬として承認された生物製剤
    • ベリムマブ
  • 承認適応症外使用の生物製剤
    • 抗CD20抗体:リツキシマブ
  • 小分子化合物

第6章 未対応のニーズ

  • 効能と安全性
  • アテローム性動脈硬化予防の必要性
  • ステロイド使用の頻度と期間を減らすためのステロイド節減療法
  • 個々の患者に特化した治療法
  • 神経認知機能障害の予防
  • 骨粗しょう症と骨壊死の予防
  • 早期診断

第7章 新たな治療法

  • 医薬品開発と規制面の課題
  • 新たな治療法
  • B細胞モジュレーター
  • T細胞モジュレーター
  • 免疫抑制薬と細胞毒性薬
  • 炎症性サイトカイン阻害剤

第8章 市場の展望

  • 米国
  • フランス
  • ドイツ
  • 英国
  • スペイン
  • イタリア
  • 日本

第9章 特許

第10章 主要企業のプロファイル

  • ANTHERA PHARMACEUTICALS INC
  • BIOTEST AG
  • BIOTICA TECHNOLOGY LTD.
  • CEPHALON
  • CORNERSTONE THERAPEUTICS INC.
  • CREABILIS THERAPEUTICS S.R.L.
  • DYNAVAX TECHNOLOGIES
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE LTD
  • GLAXOSMITHKLINE PLC (GSK)
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
  • HANSA MEDICAL AB
  • HARBOR BIOSCIENCES
  • IMMUNOMEDICS, INC.
  • IDERA PHARMACEUTICALS INC.
  • IMMUPHARMA PLC
  • JOHNSON & JOHNSON LTD.
  • ISOTECHNIKA PHARMA INC
  • KINETA INC.
  • キョーリン製薬
  • LYCERA CORPORATION
  • MERCK KGAA
  • MACROGENICS, INC.
  • NOVO NORDISK
  • NEOVACS S.A.
  • NASVAX LTD.
  • ONYX PHARMACEUTICALS INC.
  • PHARMACYCLIS
  • PORTOLA PHARMACEUTICALS INC.
  • PFIZER LIMITED
  • REVO BIOLOGICS
  • RIGEL PHARMACEUTICALS INC
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UCB GROUP/ IMMUNOMEDICS
  • VACCINEX INC.

図表リスト

目次
Product Code: PHM159A

The global market for drugs to treat systemic lupus erythematosus (SLE) is expected to reach $950.2 million in 2013 and $2.6 billion in 2018, a compound annual growth rate (CAGR) of 22.4%.

This report provides:

  • An overview of the global market for drugs and therapeutics used to treat systemic lupus erythematosus (SLE)
  • Analyses of global market trends, with data from 2013 and projections of CAGRs through 2018.
  • Analyses of factors influencing market demand such as the industry's structure, governmental regulations, and developing technologies
  • Details concerning the developmental product pipeline for therapeutics uesd to treat SLE
  • Profiles of leading companies in the industry.

STUDY GOALS AND OBJECTIVES

BCC Research's goal in conducting this study was to determine the current status of systemic lupus erythematosus (SLE) disease treatments and assess the growth potential of this area over a five-year period, from 2013 to 2018. Our key objective was to present a comprehensive analysis of the current pipeline of therapeutics, analyze the market and forecast for SLE therapeutics along with outlining the key factors that will influence this therapeutic area in the next few years.

REASONS FOR DOING THIS STUDY

SLE is a devastating and chronic autoimmune disorder affecting almost all the organs, with only one approved marketed drug- making this a significant area of unmet medical need. But there are now numerous companies developing novel treatments. This report will review the programs in development and quantify the market opportunities in SLE drugs.

SCOPE OF REPORT

The scope of this report focuses on the pharmaceutical segment. We have compiled a study of the market, as well as current and emerging modes of treatment. We present the market segment's economic environment, market factors and potential, and forecasts for 2013 to 2018. This study will be of interest to the drug industry, patients and the medical community. It will also be of interest to suppliers of products and services to this market area.

ANALYST'S CREDENTIALS

Dr. Sanjukta Bhattacharyya is the BCC Research analyst of this report. She holds a PhD in endocrinology from the University of Calcutta in India, and has more than 14 years of experience in the pharmaceutical industry, having been associated with leading pharmaceutical companies in clinical research and project management. Of note was the successful clinical development of an antimalarial new chemical entity (NCE) (Synriam), leading to its regulatory submission and transitioning to market. Synriam became the first new drug by an Indian pharmaceutical company. Sanjukta has played significant roles in various licensing deals and alliance management for NCE codevelopment between partners. Skilled in ICH/GCP guidelines and protocols, and experienced in conducting clinical trials, Sanjukta also does medical writing involving the preparation of clinical study protocols, various relevant documents, and study reports. She also has several publications in peer-reviewed journals.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • STUDY GOALS AND OBJECTIVES
  • REASONS FOR DOING THIS STUDY
  • SCOPE OF REPORT
  • INTENDED AUDIENCE
  • METHODOLOGY
  • INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH ONLINE SERVICES
  • DISCLAIMER

CHAPTER 2 - EXECUTIVE SUMMARY

  • SUMMARY TABLE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)
  • SUMMARY FIGURE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)
  • SUMMARY TABLE B: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY FIGURE B: GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)
    • KEY FACTORS DRIVING THE MARKET
    • KEY FACTORS RESTRICTING THE MARKET
    • NOTABLE PIPELINE ACTIVITIES
    • KEY CHALLENGES IN THE MARKET FOR SLE THERAPIES
    • KEY OPPORTUNITIES IN THE MARKET FOR SLE THERAPIES
  • SUMMARY TABLE C SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018

CHAPTER 3 - OVERVIEW

  • SIGNS AND SYMPTOMS
  • TYPES OF LUPUS
    • SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
    • CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
    • DRUG-INDUCED LUPUS
    • NEONATAL LUPUS ERYTHEMATOSUS
  • PATHOPHYSIOLOGY
    • DISEASE DEFINITION
    • CLINICAL MANIFESTATIONS
      • TABLE 1: PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE
      • TABLE 2: DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS
      • TABLE 3: CLASSIFICATION OF LUPUS NEPHRITIS
      • TABLE 4: WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS
  • PROGRESSION AND SEVERITY
  • ETIOLOGY
    • GENETIC FACTORS
    • ENVIRONMENTAL FACTORS
      • Ultraviolet Light:
    • HORMONAL FACTORS
  • EPIDEMIOLOGY AND PATIENT POPULATIONS
    • U.S.
    • FRANCE
    • GERMANY
    • U.K.
    • SPAIN
    • ITALY
    • JAPAN
  • DIAGNOSED AND DRUG TREATED POPULATION
    • TABLE 5: DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION

CHAPTER 4 - CURRENT MEDICAL PRACTICE AND MARKET PROFILES

  • DIAGNOSIS SCREENING AND PUBLIC AWARENESS
    • KEY DIAGNOSTIC TESTS
      • Serologic Tests
        • Anti-nuclear Antibody (ANA)
        • Antibodies to Extractable Nuclear Antigens (ENAs)
        • Prognostic Markers and the Role of Autoantibodies
  • CLINICAL RECOMMENDATIONS AND DIAGNOSIS ALGORITHM
    • FIGURE 1: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • DIFFERENTIAL DIAGNOSIS
    • TABLE 6: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS
    • FIGURE 2: PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 3: TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    • TABLE 7: TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS
  • REFERRAL PATTERNS
    • U.S.
    • FRANCE
    • GERMANY
    • U.K.
    • SPAIN
    • ITALY
    • JAPAN

CHAPTER 5 - CURRENT THERAPIES

  • TABLE 8: CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM
  • ANTIMALARIAL DRUGS
  • NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS)
  • CORTICOSTEROIDS
  • CYTOTOXIC AND IMMUNOSUPPRESSIVE DRUGS
    • CYCLOPHOSPHAMIDE
      • Azathioprine
    • MYCOPHENOLATE MOFETIL
    • METHOTREXATE
    • CYCLOSPORINE
    • TACROLIMUS
  • BIOLOGICS
    • B-CELL TARGETED THERAPY
    • BLYS-BLOCKERS (BELIMUMAB)
  • BIOLOGICS APPROVED FOR TREATING SLE
    • BELIMUMAB
      • TABLE 9: BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)
      • TABLE 10: ENDPOINTS USED IN CLINICAL TRIALS FOR SLE
  • BIOLOGICS USED OFF-LABEL
    • ANTI-CD20 ANTIBODY: RITUXIMAB (RITUXAN/MABTHERA; BIOGEN IDEC/ROCHE/ZENYAKU KOGYO)
  • SMALL MOLECULES
    • TABLE 11: CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED
    • TABLE 12: TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY
    • TABLE 13: STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY

CHAPTER 6 - UNMET NEEDS

  • EFFICACY AND SAFETY
  • NEED FOR PREVENTION OF ATHEROSCLEROSIS
  • STEROID SPARING THERAPY TO REDUCE THE DOSE AND DURATION OF STEROID USE
  • THERAPIES TAILORED TO INDIVIDUAL PATIENTS
  • PREVENTION OF NEUROCOGNITIVE DYSFUNCTION
  • PREVENTION OF OSTEOPOROSIS AND OSTEONECROSIS
  • EARLY DIAGNOSIS

CHAPTER 7 - EMERGING THERAPIES

  • DRUG DEVELOPMENT AND REGULATORY CHALLENGES
  • EMERGING THERAPIES
  • B-CELL MODULATORS
    • BELIMUMAB
    • ATACICEPT
    • EPRATUZUMAB
    • TABALUMAB:
    • RIGERIMOD
    • BLISIBIMOD
  • T-CELL MODULATORS
  • IMMUNOSUPPRESSIVE AND CYTOTOXIC DRUGS
  • PROINFLAMMATORY AND CYTOKINE INHIBITORS
    • ANTI-IFN-A/γ
      • TABLE 14: EMERGING THERAPIES BY PHASES OF DEVELOPMENT
      • TABLE 15: NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT
      • FIGURE 4: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE
      • TABLE 16: POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE

CHAPTER 8 - MARKET OUTLOOK

  • TABLE 17: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
  • TABLE 18: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 ($ MILLIONS)
  • TABLE 19: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • FIGURE 5: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
  • UNITED STATES
    • TABLE 20: U.S.- SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • FIGURE 6: U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • FRANCE
    • TABLE 21: FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 7: FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • GERMANY
    • TABLE 22: GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 8: GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • U.K.
    • TABLE 23: U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 9: U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • SPAIN
    • TABLE 24: SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 10: SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • ITALY
    • TABLE 25: ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 11: ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
  • JAPAN
    • TABLE 26: JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • FIGURE 12: JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • TABLE 27: SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 28: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 29: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 ($ MILLIONS)
    • TABLE 30: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY,THROUGH 2018 ($ MILLIONS)
    • TABLE 31: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 ($ MILLIONS)
    • TABLE 32: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 ($ MILLIONS)

CHAPTER 9 - PATENTS

  • TABLE 35: NO. OF PATENTS
  • TABLE 36: ISSUED PATENTS
  • TABLE 37: PATENT APPLICATIONS

CHAPTER 10 - COMPANY PROFILES

  • ANTHERA PHARMACEUTICALS INC
  • BIOTEST AG
  • BIOTICA TECHNOLOGY LTD.
  • CEPHALON
  • CORNERSTONE THERAPEUTICS INC.
  • CREABILIS THERAPEUTICS S.R.L.
  • DYNAVAX TECHNOLOGIES
  • ELI LILLY
  • F. HOFFMANN-LA ROCHE LTD
    • EVENTS OF 2013 AND 2014
  • GLAXOSMITHKLINE PLC (GSK)
  • HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT
  • HANSA MEDICAL AB
  • HARBOR BIOSCIENCES
  • IMMUNOMEDICS, INC.
  • IDERA PHARMACEUTICALS INC.
  • IMMUPHARMA PLC
  • JOHNSON & JOHNSON LTD.
  • ISOTECHNIKA PHARMA INC
  • KINETA INC.
  • KYORIN PHARMACEUTICALS CO. LTD
  • LYCERA CORPORATION
  • MERCK KGAA
  • MACROGENICS, INC.
  • NOVO NORDISK
  • NEOVACS S.A.
  • NASVAX LTD.
  • ONYX PHARMACEUTICALS INC.
  • PHARMACYCLIS
  • PORTOLA PHARMACEUTICALS INC.
  • PFIZER LIMITED
  • REVO BIOLOGICS
  • RIGEL PHARMACEUTICALS INC
  • SANOFI
  • TEVA PHARMACEUTICAL INDUSTRIES LTD.
  • UCB GROUP/ IMMUNOMEDICS
  • VACCINEX INC.

LIST OF TABLES

  • SUMMARY TABLE A: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, THROUGH 2018 (MILLIONS)
  • SUMMARY TABLE B: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
  • SUMMARY TABLE C: SUMMARY OF KEY PARAMETERS OF SYSTEMIC LUPUS ERYTHEMATOSUS MARKET, THROUGH 2018
    • TABLE 1: PERCENTAGE OF PATIENTS WITH DIFFERENT CLINICAL MANIFESTATIONS OF SLE DISEASE
    • TABLE 2: DESCRIPTION OF DIFFERENT TYPES OF SLE DISEASE MANIFESTATIONS
    • TABLE 3: CLASSIFICATION OF LUPUS NEPHRITIS
    • TABLE 4: WORLD HEALTH ORGANIZATION CLASSIFICATION OF LUPUS NEPHRITIS
    • TABLE 5: DIAGNOSED PREVALENCE AND DRUG TREATED SLE PATIENT POPULATION
    • TABLE 6: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON MANIFESTATIONS
    • TABLE 7: TREATMENT ALGORITHM OF SYSTEMIC LUPUS ERYTHEMATOSUS
    • TABLE 8: CURRENT DRUGS USED IN THE TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS AND THEIR MECHANISM
    • TABLE 9: BELIMUMAB EFFICACY DATA (BLISS-52: PRIMARY ENDPOINT AND COMPONENTS OF SLE RESPONDER INDEX)
    • TABLE 10: ENDPOINTS USED IN CLINICAL TRIALS FOR SLE
    • TABLE 11: CURRENT THERAPIES FOR SYSTEMIC LUPUS ERYTHEMATOSUS, TREATMENT BY DAILY DOSE AND THE MANIFESTATION TARGETED
    • TABLE 12: TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON ORGAN INVOLVEMENT AND DISEASE SEVERITY
    • TABLE 13: STEROIDS USED FOR TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS ACROSS DIFFERENT DISEASE SEVERITY
    • TABLE 14: EMERGING THERAPIES BY PHASES OF DEVELOPMENT
    • TABLE 15: NUMBER OF PROGRAMS AT EACH CLINICAL PHASES OF CLINICAL DEVELOPMENT
    • TABLE 16: POSITIONING OF LEADING EMERGING THERAPIES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS IN THE FUTURE
    • TABLE 17: GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • TABLE 18: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET -SALES IN MAJOR MARKETS, THROUGH 2018 ($ MILLIONS)
    • TABLE 19: GLOBAL SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 20: U.S.- SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 ($ MILLIONS)
    • TABLE 21: FRANCE: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 22: GERMANY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 23: U.K.: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 24: SPAIN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 25: ITALY: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 26: JAPAN: SALES OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 27: SALES OF BIOLOGICS AND SMALL MOLECULE DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, THROUGH 2018 ($ MILLIONS)
    • TABLE 28: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.S., THROUGH 2018 ($ MILLIONS)
    • TABLE 29: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF FRANCE, THROUGH 2018 ($ MILLIONS)
    • TABLE 30: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF GERMANY,THROUGH 2018 ($ MILLIONS)
    • TABLE 31: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF THE U.K., THROUGH 2018 ($ MILLIONS)
    • TABLE 32: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF SPAIN, THROUGH 2018 ($ MILLIONS)
    • TABLE 33: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF ITALY, THROUGH 2018 ($ MILLIONS)
    • TABLE 34: SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS IN THE MAJOR PHARMACEUTICAL MARKET OF JAPAN, THROUGH 2018 ($ MILLIONS)
    • TABLE 35: NO. OF PATENTS
    • TABLE 36: ISSUED PATENTS
    • TABLE 37: PATENT APPLICATIONS

LIST OF FIGURES

  • SUMMARY FIGURE A GLOBAL SALES OF DRUGS TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2012-2018 (%)
  • SUMMARY FIGURE B GLOBAL SLE MARKET-SHARE OF DRUG CLASSES USED TO TREAT SYSTEMIC LUPUS ERYTHEMATOSUS, 2012-2018 (%)
    • FIGURE 1: DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 2: PATIENT CARE PATH IN SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 3: TREATMENT DECISION TREE FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    • FIGURE 4: NUMBER OF PROGRAMS AT EACH CLINICAL PHASE
    • FIGURE 5: GLOBAL SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018
    • FIGURE 6: U.S. SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 7: FRANCE: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 8: GERMANY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 9: U.K: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 10: SPAIN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 11: ITALY: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
    • FIGURE 12: JAPAN: SYSTEMIC LUPUS ERYTHEMATOSUS MARKET 2013-2018-VALUE OF DRUG CLASSES, 2013 AND 2018 ($ MILLIONS)
Back to Top